Title
Abobotulinumtoxina (Dysport®), onabotulinumtoxina (botox®), and incobotulinumtoxina (xeomin®) neurotoxin content and potential implications for duration of response in patients
Author
Field, M.
Splevins, A.
Picaut, P.
van der Schans, M.
Langenberg, J.
Noort, D.
Foster, K.
Publication year
2018
Abstract
Botulinum neurotoxin type-A (BoNT-A) blocks the release of acetylcholine from peripheral cholinergic nerve terminals and is an important option for the treatment of disorders characterised by excessive cholinergic neuronal activity. Several BoNT-A products are currently marketed, each with unique manufacturing processes, excipients, formulation, and non-interchangeable potency units. Nevertheless, the effects of all the products are mediated by the 150 kDa BoNT-A neurotoxin. We assessed the quantity and light chain (LC) activity of BoNT-A in three commercial BoNT-A products (Dysport®; Botox®; Xeomin®). We quantified 150 kDa BoNT-A by sandwich ELISA and assessed LC activity by EndoPep assay. In both assays, we assessed the results for the commercial products against recombinant 150 kDa BoNT-A. The mean 150 kDa BoNT-A content per vial measured by ELISA was 2.69 ng/500 U vial Dysport®, 0.90 ng/100 U vial Botox®, and 0.40 ng/100 U vial Xeomin®. To present clinically relevant results, we calculated the 150 kDa BoNT-A/US Food and Drug Administration (FDA)-approved dose in adult upper limb spasticity: 5.38 ng Dysport® (1000 U; 2 × 500 U vials), 3.60 ng Botox® (400 U; 4 × 100 U vials), and 1.61 ng Xeomin® (400 U; 4 × 100 U vials). EndoPep assay showed similar LC activity among BoNT-A products. Thus, greater amounts of active neurotoxin are injected with Dysport®, at FDA-approved doses, than with other products. This fact might explain the long duration of action reported across multiple indications, which benefits patients, caregivers, clinicians, and healthcare systems. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
Subject
Observation, Weapon & Protection Systems
CBRN - CBRN Protection
Botulinum toxin
BoNT
Spasticity
Dysport®
AbobotulinumtoxinA
Glabellar
Lines
To reference this document use:
http://resolver.tudelft.nl/uuid:2f39b1e7-d5f2-46e8-b5e8-b9d37e42259c
DOI
https://doi.org/10.3390/toxins10120535
TNO identifier
858042
Publisher
MDPI AG, Rijswijk
ISSN
2072-6651
Source
Toxins, 10 (12)
Article number
535
Document type
article